News Releases

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering